BioStock: BioInvent’s CEO on the benefits of a diversified portfolio

In just three years, immuno-oncology company BioInvent has expanded its project portfolio and advanced from one to soon five drug candidates in clinical phase I/IIa, raised nearly one billion SEK in venture capital and entered into agreements with global pharmaceutical companies. BioStock got in touch with President and CEO Martin Welschof, to get his recipe for building a successful, large international company.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2021/09/bioinvents-ceo-on-the-benefits-of-a-diversified-portfolio/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se